The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Canc

The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT05496166 by Shanghai Pulmonary Hospital, Shanghai, China, with a registry enrolment figure of 348 participants, started 2023-08-01 and due to reach its primary completion in 2027-08-01. Interventions recorded: chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy. Conditions listed: Limited Stage Small Cell Lung Cancer. Primary outcome: progression-free survival. Lung eligibility wording from the registry: "* Histologically or cytologically confirmed SCLC, imaging examination and other confirmed limited-stage small cell lung cancer, and without previous treatment;". Sites: China. No results are recorded here; the registry entry is the source.